Therapeutic strategies for RA are like those for SLE, such as blocking surface markers, such as CD19 and CD11b/c, and inhibiting activation-related cytokines like IL-21 and IFN, as well as TLR and JAK/STAT signaling. This evidence concerns the gene CD19 and rheumatoid arthritis.